Physician profile
Larry Culpepper
NPI 1225001076
$108,577.12
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53K · 2020: $4,049 · 2021: $12K · 2022: $22K · 2023: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Travel and Lodging: $176 · Food and Beverage: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,324.00 |
| Travel and Lodging | $175.88 |
| Food and Beverage | $133.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $33,937.43 | 2019-2022 | |
| Abbvie INC. | $15,774.47 | 2021-2023 | Vraylar |
| Supernus Pharmaceuticals, INC. | $12,347.09 | 2021-2022 | |
| Biogen, INC. | $10,324.00 | 2023 | Zurzuvae |
| Acadia Pharmaceuticals INC | $10,144.99 | 2019 | |
| Merck Sharp & Dohme LLC | $9,092.64 | 2019-2020 | |
| Allergan, INC. | $6,814.04 | 2019-2020 | |
| Shire North American Group INC | $6,372.46 | 2019 | |
| Sunovion Pharmaceuticals INC. | $2,520.00 | 2020-2022 | |
| Alkermes, INC. | $1,250.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Culpepper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.